"Correlation in quality and metabolism" of multicomponents in Angelicae Sinensis Radix / 中草药

Objective: To study the dynamic processes of in vivo metabolism of multicomponent in the decoction of Angelicae Sinensis Radix (ASR), select the quality control components, look for a new quality evaluation method for Chinese materia medica (CMM). Methods: The blood was taken from mesenteric vein and abdominal aorta. By analyzing HPLC fingerprints of intestinal metabolism and liver metabolism, we could infer multicomponent changes in the metabolic process of water extract from ASR. Results: Totally 15 components were basically stable in the digestive juice, four of them may be metabolized by intestine, while seven of them were metabolized by liver. And we found one new component was the metabolite of liver, seven new components were the metabolites of intestine, but five of them were metabolized by liver and could not be absorbed into blood. Finally, we identified that four prototype components of water extract from ASR and three metabolites could be absorbed into blood. Conclusion: Based on the multicomponent metabolic profiling of ASR, we initially select the four prototype components including senkyunolide I as the quality control component, and we finally establish a quality evaluation method for "correlation in quality and metabolism".

Clinical manifestations, laboratory test, treatment and outcome of neuropsychiatric involvement in pediatric systemic lupus erythematosus patients / 中华儿科杂志

<p><b>OBJECTIVE</b>To investigate the clinical manifestations, laboratory test, treatment and outcome of neuropsychiatric (NP) involvement in pediatric systemic lupus erythematosus (SLE) patients.</p><p><b>METHODS</b>Seventy-seven patients with NP syndromes of SLE (NPSLE) seen from 1987 to 2007 were retrospectively reviewed. The relationship between the relative factors and the relapse of NPSLE was analyzed with logistic regression model.</p><p><b>RESULTS</b>NPSLE was found in 17.3% of the SLE patients and 75% of the NPSLE patients the NP involvements occurred in the first 2 years of the onset of SLE. The most frequent NP manifestations were headache (31.8%) and seizure disorder (29.1%). In the active phases, the levels of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores of the 92.2% patients were higher than 15 and belonged to severe lupus. The patients were accompanied frequently with fever (88.3%) and rash (84.4%). The most frequently involved organs were kidney (76.6%) and blood system (67.5%). In the active phases, the ANA was positive (98.7%), the level of ESR increased (86.3%), the level of complement profile decreased (72.7%). The cerebrospinal fluid (CSF) study, the CT, the MRI and the EEG were abnormal (90.1%, 60.7%, 54.8%, 73.9%, respectively). All the patients received glucocorticoids and immunodepressant treatment in which 79.2% received IV high-dose methylprednisolone (MP), 51.9% received intrathecal (IT) methotrexate (MTX) and dexamethasone (DXM), 26.0% received IVIG, 2 patients received autologous peripheral blood stem cell transplantation. The mortality was 9.0%. The rate of relapse was 22.0% and in 75.0% of relapsed patients the relapse occurred within 24 months from the onset of NPSLE. The SLEDAI scores related to the relapse of the NPSLE (chi(2) = 3.987, P = 0.0459, OR = 1.172, 95% CI 1.003 and 1.370).</p><p><b>CONCLUSION</b>SLEDAI scores were significantly helpful in predicting recurrence of NPSLE.</p>

Study on topiramate as add-on drug treating severe epilepsy in infants / 实用儿科临床杂志

Objective To evaluate the efficacy and safety of topiramate(TPM) as add - on drug treating infants with severe epilepsy. Methods We performed prospective label add - on study in 12 infants (aged 4 to 19 months) with sever seizures of different types. TPM was add - on one or more other baseline drugs and the efficacy was evaluated according to seizure type and frequency Results TPM initiated in a daily dose of 0.5 - 1 0 mg/kg, followed by a 1 - 2 weeks titration on the increase of 0 5 - 1.0 mg/kg up to a maximum daily dose of 4 - 10 mg/kg. After a mean period of 6 2 months (range 3- 13 montks), Total efficacy was 75 % and 50 % were controlled completely. Seizure frequency was unchanged in 3 patients (25 % ). As for seizure type, TPM was more effective in complex partial as compared with generalized tonic-conic seizures. Mild adverse events were present in 3 patients (25 %), represented hypersonia, fever and decreased speech. Conclusions TPM may be a available drug in infants with severe epilepsy. It is safe, with mild adverse effect in fewer patients.JAppl Clin Pediatr,2004,19(11):986-987